CZO.V - Ceapro Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.5500
+0.0300 (+5.77%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.5200
Open0.5300
Bid0.5300 x 0
Ask0.5500 x 0
Day's Range0.5200 - 0.5500
52 Week Range0.1400 - 0.5600
Volume19,600
Avg. Volume64,904
Market Cap42.685M
Beta (5Y Monthly)2.03
PE Ratio (TTM)68.75
EPS (TTM)0.0080
Earnings DateApr. 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.08
  • GlobeNewswire

    Ceapro Announces Results of 2020 Shareholders’ Meeting

    EDMONTON, Alberta, June 22, 2020 -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and.

  • GlobeNewswire

    Ceapro Inc. Announces Publication of Positive Results for a PGX Processed Drug Delivery System for Accelerated Burn Wound Healing

    – Results from successful drug-impregnation of PGX liquid processed alginate hydrogel scaffolds further bolsters Ceapro’s efforts to develop innovative delivery systems composed.

  • GlobeNewswire

    Ceapro Inc. to Present at the Virtual Investor Fireside Chat Series

    Ceapro Inc.  (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro will present at the Virtual Investor Fireside Chat Series on Wednesday, June 17, 2020 at 10:00 AM ET. A live video webcast of the fireside chat will be available on the IR Calendar page of the Investors section of the Company’s website (www.ceapro.com).

  • GlobeNewswire

    Ceapro Inc. Reports 2020 First Quarter Financial Results and Highlights

    – Maintained production operations during COVID-19 pandemic crisis, providing our customers essential products while ensuring the health and safety of our employees – –.

  • GlobeNewswire

    Ceapro Inc. Expands Collaborative Research Program with McMaster University to Develop Inhalable Therapeutic for COVID-19

    Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced it has entered into an additional research project expanding on the ongoing collaboration with McMaster University to develop an inhalable therapeutic for COVID-19. The project will be under the leadership of Dr. Kjetil Ask, a pulmonary fibrosis expert, and Dr. Todd Hoare respectively from departments of Medicine and Chemical Engineering at McMaster University.

  • GlobeNewswire

    Ceapro Inc. Reports Fourth Quarter and Full Year 2019 Results and Highlights

    EDMONTON, Alberta, April 16, 2020 -- Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and.

  • GlobeNewswire

    Ceapro Inc. to Present at the April 2020 Virtual Investor Summit

    Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro will present at the April 2020 Virtual Investor Summit on Wednesday, April 22, 2020 at 1:00 PM ET. A live audio webcast of the presentation will be available on the IR Calendar page of the Investors section of the Company’s website (www.ceapro.com).

  • If You Had Bought Ceapro (CVE:CZO) Stock Three Years Ago, You'd Be Sitting On A 87% Loss, Today
    Simply Wall St.

    If You Had Bought Ceapro (CVE:CZO) Stock Three Years Ago, You'd Be Sitting On A 87% Loss, Today

    Every investor on earth makes bad calls sometimes. But really bad investments should be rare. So consider, for a...

  • GlobeNewswire

    Ceapro Inc. Receives Research License from Health Canada Controlled Substances and Cannabis Branch

    EDMONTON, Alberta, Feb. 14, 2020 -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and.

  • GlobeNewswire

    Ceapro Inc. to Present at Noble Capital Markets’ 16th Annual Investor Conference

    Ceapro Inc.  (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, will present at NobleCon16 - Noble Capital Markets’ 16th Annual Investor Conference on Monday, February 17, 2020 at 3:30 p.m. ET in Hollywood, Florida. As part of his presentation, Mr. Gagnon, will provide a corporate overview and an update on the Company's transition to a new business model from a contract manufacturer to a biopharmaceutical development company. As part of the Company's growth strategy, Ceapro is developing its two value drivers, the pharmaceutical grade active ingredients avenanthramides and beta glucan, into different formulations to enable the Company's transition into other sectors including nutraceuticals and pharmaceuticals.

  • GlobeNewswire

    Ceapro Inc. Announces Approval from Health Canada for Protocol Expansion of Current Clinical Study Assessing Beta Glucan as a Cholesterol-Lowering Agent

    Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced it has received approval from Health Canada to expand the inclusion criteria of its comparison study evaluating high-medium molecular weight beta glucan as an add-on therapy to statins in subjects with hyperlipidemia. While the total number of patients will remain the same, this expansion will allow evaluation of enrolled subjects with confirmed pathophysiological condition of hyperlipidemia who voluntarily request to be treated with beta glucan only, without regular dosing of statins.

  • GlobeNewswire

    Ceapro Inc. Secures DTC Eligibility for Publicly Traded Shares Under Ticker OTCQZ: CRPOF

    Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that its shares have received Depository Trust Company (“DTC”) full-service eligibility in the United States. DTC eligibility is expected to simplify and accelerate the process of trading and transferring of the Company's common shares in the United States.

  • How Does Investing In Ceapro Inc. (CVE:CZO) Impact The Volatility Of Your Portfolio?
    Simply Wall St.

    How Does Investing In Ceapro Inc. (CVE:CZO) Impact The Volatility Of Your Portfolio?

    Anyone researching Ceapro Inc. (CVE:CZO) might want to consider the historical volatility of the share price. Modern...

  • GlobeNewswire

    Ceapro Announces Grant of Stock Options and Restricted Share Units

    Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the granting of stock options (“options”) and restricted share units (“RSUs”) to all employees, officers and directors of the Company. Options to purchase 380,000 common shares were granted pursuant to the Company’s Stock Option Plan, with an exercise price of $0.36 per common share.

  • GlobeNewswire

    Ceapro Inc. Announces Publication of Results for a New PGX Processed Chemical Complex in the Journal of Supercritical Fluids

    The main objective of this study was to investigate the preparation of coenzyme Q10 (coQ10) loaded gum arabic (GA) using the Pressurized Gas eXpanded (PGX) liquid technology and adsorptive precipitation processes. It was found that PGX could effectively dry, purify and increase the surface area of GA.

  • How Much Did Ceapro Inc.'s (CVE:CZO) CEO Pocket Last Year?
    Simply Wall St.

    How Much Did Ceapro Inc.'s (CVE:CZO) CEO Pocket Last Year?

    Gilles Gagnon has been the CEO of Ceapro Inc. (CVE:CZO) since 2012. This analysis aims first to contrast CEO...

  • GlobeNewswire

    Ceapro Inc. Reports 2019 Third Quarter Financial Results and Operational Highlights

    - Continued execution on transition to a new business model from contract manufacturer to biopharmaceutical company - - Maintained R&D focus on the development of delivery.

  • GlobeNewswire

    Ceapro Inc. Announces Issuance of U.S. and European Patent for Flagship Product, Avenanthramides

    OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the European and U.S. Patent and Trademark Offices have issued the Company European Patent No. 2411527 and U.S. Patent No. 10,334,869 entitled, “Method For Increasing Concentration of Avenanthramides in Oats,” related to the production of its value-driver product, avenanthramides, utilizing a malting technology in-licensed from Agriculture and Agri-Food Canada. Ceapro's flagship product, avenanthramides, is a group of phenolic alkaloids compounds uniquely found in oats and produced using a proprietary patented process.

  • GlobeNewswire

    Ceapro Begins Trading on the OTCQX Best Market

    Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that its common shares have been approved for trading onto the OTCQX® Best Market, a U.S. market that is operated by the OTC Markets Group in New York.

  • Did You Manage To Avoid Ceapro's (CVE:CZO) Devastating 80% Share Price Drop?
    Simply Wall St.

    Did You Manage To Avoid Ceapro's (CVE:CZO) Devastating 80% Share Price Drop?

    Ceapro Inc. (CVE:CZO) shareholders should be happy to see the share price up 13% in the last quarter. But only the...

  • GlobeNewswire

    Ceapro to Present PGX Technology at the 3rd International Symposium on Pharmaceutical Engineering Research

    Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that during a podium presentation, Dr. Bernhard Seifried, Senior Director, Engineering Research & Technologies at Ceapro, will present at the 3rd International Symposium on Pharmaceutical Engineering Research (“SPhERe”) being held September 25-27, 2019 in Braunschweig, Germany.

  • GlobeNewswire

    Ceapro Inc. to Present at the Fall Investor Summit in New York

    Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, will present at the Fall Investor Summit on Monday, September 16, 2019 at 2:30 PM EDT in New York, NY. For more information about the conference, please click here to visit the conference website.

  • GlobeNewswire

    Ceapro Inc. Reports 2019 Second Quarter and Six-Month Financial Results and Operational Highlights

    - Continued execution on transition to a new business model from contract manufacturer to biopharmaceutical company - - Increased R&D investment focused on the development.

  • GlobeNewswire

    Ceapro Announces Research Funding Award from the Canadian Institutes of Health Research and the Natural Sciences and Engineering Research Council of Canada for Joint Projects with McMaster University

    Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Canadian Institutes of Health Research (CIHR) in partnership with the Natural Sciences and Engineering Research Council of Canada (NSERC) has awarded a $670,315 Collaborative Health Research Projects (CHRP) Initiative grant for a three-year collaborative project with Dr. Todd Hoare, Dr. Brian Coombes and Dr. Kjetil Ask at McMaster University. This project marks the beginning of the second phase of an extensive research program initiated in March 2016 with researchers at McMaster University under Dr. Hoare’s leadership.

  • Does Ceapro Inc. (CVE:CZO) Have A Particularly Volatile Share Price?
    Simply Wall St.

    Does Ceapro Inc. (CVE:CZO) Have A Particularly Volatile Share Price?

    If you own shares in Ceapro Inc. (CVE:CZO) then it's worth thinking about how it contributes to the volatility of your...